ANG1005 for brain metastases from breast cancer: 18F-FLT-PET and MRI as complementary approaches to response assessment.

Bates, Susan E.; Lindenberg, Maria Liza; Bryla, Christine; Pichun, Mauricio Emmanuel Burotto; Patronas, Nicholas J.; Amiri‐Kordestani, Laleh; Gonzalez, E. M.; Fojo, Tito; Balasubramaniam, Sanjeeve; Choyke, Peter L.

doi:10.1200/jco.2015.33.15_suppl.2552

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ANG1005 is currently also in Phase II clinical trials for breast cancer (ClinicalTrials.gov identifier: NCT02048059), and preliminary results show that this compound reduces tumours up to 60% in patients. 121 Angiopep-2 has been used to transport a wide variety of nanocarriers loaded with small molecules, proteins or genetic material into the CNS. These carriers include liposomes, 122,123 nanotubes, 124 dendrimers made of polyamidoamine [125][126][127][128] and poly-L-lysine, 129 and also nanoparticles made of PEGpolycaprolactam, [130][131][132][133] PEG-poly(lactic-co-glycolate) (PEG-PLGA), 134 thermoresponsive hydrogels, 135 upconversion nanocrystals 136 and gold.…”

Section: Angiopep-2: An Example Of Versatilitymentioning

confidence: 99%

Blood–brain barrier shuttle peptides: an emerging paradigm for brain delivery

et al. 2016

View full text Add to dashboard Cite

Brain delivery is one of the major challenges in drug development because of the high number of patients suffering from neural diseases and the low efficiency of the treatments available. Although the blood-brain barrier (BBB) prevents most drugs from reaching their targets, molecular vectors - known as BBB shuttles - offer great promise to safely overcome this formidable obstacle. In recent years, peptide shuttles have received growing attention because of their lower cost, reduced immunogenicity, and higher chemical versatility than traditional Trojan horse antibodies and other proteins.

show abstract